Lundquist Kevin Michael reported grant involving 500,000 derivative units of Outlook Therapeutics, Inc. at $0.00 for $0 on Sep 1, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Sep 2, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
500,000Employee Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
500,000Direct
Trade date
Sep 1, 2026Grant
Filed
Sep 2, 2026, 4:32 PM ET1-day reporting delay
Accession
0002074701-26-000005Code A · Transaction 201901
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

OTLK price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
OTLK · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +56%1w ago +4.8%1d ago +1.6%
Returns since7d +3.2%30d −8.1%90d180d1y

Footnotes in full

F1: The option was granted by Outlook Therapeutics, Inc. (the "Issuer") as an inducement material to the Reporting Person's entry into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). 25% of the shares subject to the option shall vest on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.